V. Filipazzi

422 total citations
19 papers, 195 citations indexed

About

V. Filipazzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, V. Filipazzi has authored 19 papers receiving a total of 195 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in V. Filipazzi's work include Cancer Treatment and Pharmacology (5 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). V. Filipazzi is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). V. Filipazzi collaborates with scholars based in Italy, Malaysia and United Kingdom. V. Filipazzi's co-authors include Alessandro Morabito, Adolfo Favaretto, Cesare Gridelli, Ciro Gallo, Marco Cattaneo, E. Piazza, Alessandra Bearz, Luigi Manzione, Rosario Vincenzo Iaffaioli and Francesco Carrozza and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Oncologist.

In The Last Decade

V. Filipazzi

17 papers receiving 188 citations

Peers

V. Filipazzi

ONCOL

PRM

PFM

Yana Novis Brazil

Priya Sriskandarajah United Kingdom

Alejandro Martínez Spain

Herish Garresori Norway

Anna Morelli Italy

Manuel Sánchez Cánovas Spain

Tomasz Ociepa Poland

Simona Pastorino Italy

Katell Le Dû France

Christian Platini France

Yana Novis Brazil

V. Filipazzi

78 ×0.6

ONCOL

27 ×0.2

PRM

21 ×0.9

21 ×1.1

PFM

28 ×2.0

Citations per year, relative to V. Filipazzi V. Filipazzi (= 1×) peers Yana Novis

Countries citing papers authored by V. Filipazzi

Since Specialization

Citations

This map shows the geographic impact of V. Filipazzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Filipazzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Filipazzi more than expected).

Fields of papers citing papers by V. Filipazzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Filipazzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Filipazzi. The network helps show where V. Filipazzi may publish in the future.

Co-authorship network of co-authors of V. Filipazzi

This figure shows the co-authorship network connecting the top 25 collaborators of V. Filipazzi. A scholar is included among the top collaborators of V. Filipazzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Filipazzi. V. Filipazzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Verde, Nicla La, Giovanni Casazza, Stefania Cheli, et al.. (2021). Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. The Pharmacogenomics Journal. 21(4). 491–497. 3 indexed citations

Cona, Maria Silvia, Eliana Rulli, Davide Dalu, et al.. (2021). The emotional impact of the COVID-19 outbreak on cancer outpatients and their caregivers: results of a survey conducted in the midst of the Italian pandemic. Supportive Care in Cancer. 30(2). 1115–1125. 7 indexed citations

Cona, Maria Silvia, Davide Dalu, Eliana Rulli, et al.. (2021). COVID-19 and cancer: How outpatients (pts) and their caregivers (CGs) face to the pandemic—A survey from the midst of the Italian outbreak.. Journal of Clinical Oncology. 39(15_suppl). e24119–e24119.

Cona, Maria Silvia, et al.. (2020). 1570P The emotional impact of COVID-19 outbreak on cancer out-patients and their caregivers: Impressions from the heart of the Italian pandemic. Annals of Oncology. 31. S956–S957.

Dalu, Davide, V. Filipazzi, Anna Gambaro, et al.. (2019). ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study. Cancer Chemotherapy and Pharmacology. 83(4). 803–808. 11 indexed citations

Luciani, Andrea, Luca Toschi, S. Fava, et al.. (2018). Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience. Annals of Oncology. 29. viii533–viii533. 6 indexed citations

Morabito, Alessandro, Gennaro Daniele, Adolfo Favaretto, et al.. (2015). A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients. The STAD-1 trial.. Journal of Clinical Oncology. 33(15_suppl). 7505–7505. 1 indexed citations

Fagnani, Daniele, V. Filipazzi, Marco Danova, et al.. (2014). Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study. Tumori Journal. 100(5). 491–498. 12 indexed citations

Gridelli, Cesare, Antônio Rossi, Massimo Di Maïo, et al.. (2013). Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 15(2). 166–170. 21 indexed citations

10.

Gridelli, Cesare, Ciro Gallo, Alessandro Morabito, et al.. (2011). Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. Journal of Thoracic Oncology. 7(1). 233–242. 5 indexed citations

11.

Oteri, Alessandro, María Teresa Cattaneo, V. Filipazzi, et al.. (2009). A Case of Bullous Dermatitis Induced by Erlotinib. The Oncologist. 14(12). 1201–1204. 3 indexed citations

12.

Fagnani, Daniele, E. Menatti, Mary Duro, et al.. (2007). Cetuximab and irinotecan (CPT11) salvage treatment for colorectal cancer (CRC) in progression after two or more chemotherapy (CT) lines: The POLONORD Group experience. Journal of Clinical Oncology. 25(18_suppl). 14575–14575. 1 indexed citations

13.

Gridelli, Cesare, Paolo Maione, Alfonso Illiano, et al.. (2007). Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The MILES-2P Studies. Journal of Clinical Oncology. 25(29). 4663–4669. 60 indexed citations

14.

Fagnani, Daniele, Riccardo Franchi, Camillo Porta, et al.. (2006). Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Annals of Oncology. 18(3). 551–555. 23 indexed citations

15.

Fagnani, Daniele, Riccardo Franchi, Camillo Porta, et al.. (2006). Antithrombotic prophylaxis (AP) and catether-related infections in cancer patients (pts) carrying central venous devices (CVD): An observational study. Journal of Clinical Oncology. 24(18_suppl). 18550–18550. 1 indexed citations

16.

Conconi, Annarita, Catherine Thieblemont, Andrés J.M. Ferreri, et al.. (2002). Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type). 7 indexed citations

17.

Frontini, Luciano, et al.. (1996). Cisplatin-Vinorelbine Combination Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer. Tumori Journal. 82(1). 57–60. 10 indexed citations

18.

Piazza, E., V. Filipazzi, L. Isa, et al.. (1994). Cisplatin-vinorelbine (DDP+VBN) association chemotherapy in the treatment of locally advanced N.S.C.L.C.. Lung Cancer. 11. 128–128. 2 indexed citations

19.

Cattaneo, Marco, et al.. (1988). Transient blindness and seizure associated with cisplantin therapy. Journal of Cancer Research and Clinical Oncology. 114(5). 528–530. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact